| 17-May-13 10:00PM | Dow Jumps on Virtuous Cycle at Motley Fool |
| 08:52PM | Oncothyreon A Speculative Buy at Seeking Alpha |
| 06:33PM | 3 Most Important Upcoming FDA Decisions of 2013 at Motley Fool |
| 03:45PM | Merck to Present at the UBS Global Healthcare Conference Business Wire |
| 03:26PM | Why Stocks Are Continuing Their Climb at Motley Fool |
| 01:43PM | Jennifer Aniston: Movie Star Turned Hair Care Mogul at CNBC |
| 01:03PM | Strong Consumer Sentiment Pulls Markets Higher at Motley Fool |
| 12:34PM | Credit Swaps in U.S. Fall as Leading Indicators, Sentiment Rise at Bloomberg |
| 12:00PM | Dow Today: Merck (MRK) Lower at TheStreet |
| 10:43AM | Stanley Druckenmiller's top stock picks at MarketWatch |
| 09:54AM | Petrobras, Merck Lead $54 Billion of Company Bond Sales in U.S. at Bloomberg |
| 08:30AM | Global Health, Development and Business Leaders Announce New Innovative Financing Partnership to Deliver Essential Health Supplies More Quickly and Efficiently Business Wire |
| 07:25AM | Bristol-Myers, Merck And Roche: R&D Finds Golden Pill, So Buy at Seeking Alpha |
| 16-May-13 06:32PM | Any Light at the End of the Tunnel for Alzheimer's Disease? at Motley Fool |
| 04:17PM | Bristol-Myers Drug Cocktail Stymies Melanoma Tumors at Bloomberg |
| 01:23PM | Investing in Health Care Innovation: A Wall Street Transcript Interview with Finny Kuruvilla, Portfolio Manager of the Eventide Gilead Fund Wall Street Transcript |
| 01:00PM | Markets Are Flat After Release of Poor Economic Data at Motley Fool |
| 12:04PM | DEALTALK-Novartis' Vasella exit opens door to Roche stake sale at Reuters |
| 11:30AM | BlackRock Has Alternative to Money Funds: Credit Markets at Bloomberg |
| 15-May-13 09:01PM | Melanoma Treatment Harnesses Immune System to Combat Cancer Cells at New York Times |
| 07:09PM | With 'Cell Death' Drugs, Bristol-Myers May Win No Matter What at Forbes |
| 06:30PM | InPlay: Merck prices $6.5 bln debt offering Briefing.com |
| 06:29PM | Merck Prices $ 6.5 Billion Debt Offering Business Wire |
| 06:00PM | Bristol-Myers Drug Cocktail Stymies Melanoma Tumors at Bloomberg |
| 06:00PM | ASCO '13 Preview: New 'Anti-PD-1' Therapies Shrink Tumors at TheStreet |
| 05:59PM | Roche immunotherapy shows response over range of cancers at Reuters |
| 05:59PM | Bristol melanoma drug combo marks new advance in immunotherapy at Reuters |
| 04:59PM | Why Bristol-Myers Is Soaring at Motley Fool |
| 03:08PM | AmEx, Merck Lead $16.2 Billion of Company Bond Offerings in U.S. at Bloomberg |
| 02:37PM | GE Partners With Green Waste Energy and 2 Other Dow Movers To Watch at Wall St. Cheat Sheet |
| 01:42PM | These Stocks Are Still Solid Long-Term Picks at Motley Fool |
| 01:17PM | Large Hedge Fund Levin Capital's Top Stock Picks at Seeking Alpha |
| 01:04PM | MERCK & CO. INC. Financials EDGAR Online Financials |
| 01:03PM | 5 Stocks Boosting The Drugs Industry Higher at TheStreet |
| 11:10AM | FDA Accepts Merck BLA Zacks |
| 11:01AM | 2 Red Flags for Merck's Type 2 Diabetes Blockbuster at Motley Fool |
| 09:48AM | Merck Plans Bond Offering for Stock Buybacks After Moodys Cut at Bloomberg |
| 09:32AM | This Stock Should Get Better in the Long Run at Motley Fool |
| 09:26AM | Stocks to Watch: Macy's, Pandora, Vipshop at The Wall Street Journal |
| 08:21AM | Racing Toward the Next Hepatitis C Drug Approval at Motley Fool |
| 08:18AM | Quintiles, Merck Serono announce clinical development partnership theflyonthewall.com |
| 14-May-13 06:16PM | Why This Pharma Giant Doesn't Look Good Now at Motley Fool |
| 06:11PM | Moody's lowers Merck's long-term debt rating AP |
| 06:04PM | Can Merck's Pipeline Offset The Pain From Major Patent Expirations? at Seeking Alpha |
| 04:59PM | South Korea's Celltrion sale seen slow-going as sceptics emerge at Reuters |
| 03:28PM | Don't Get Too Excited About This Cancer Drug Yet at Motley Fool |
| 02:34PM | JPMorgan Market Revenue Soars Year-Over-Year and 2 Other Dow Movers to Watch at Wall St. Cheat Sheet |
| 09:52AM | Can Allergy Season Make You Rich? at Motley Fool |
| 09:15AM | Merck to Present at the Bank of America/Merrill Lynch 2013 Healthcare Conference Business Wire |
| 08:37AM | The Conundrum Of Healthcare In India at Forbes |
| 07:01AM | Stock Market News for May 14, 2013 Zacks |
| 05:47AM | Higher prices for MS drug help drug firm Merck AP |
| 04:48AM | Higher prices for MS drug help drug firm Merck AP |
| 01:58AM | Big Pharma's Biggest Losers at Motley Fool |
| 01:50AM | Merck KGaA Profit Beats Estimates on Cost-Cutting at Bloomberg |
| 13-May-13 12:00PM | Speculation Sickens the Dow, Pharma Tries to Cure It at Motley Fool |
| 10:55AM | Buying the Pharma Dips at Motley Fool |
| 07:35AM | Stock Market News for May 13, 2013 Zacks |
| 12:00AM | Human Immune-Boosting Cancer Drugs Seen Extending Lives at Bloomberg |
| 12-May-13 04:31PM | Merck Stock: Not a Safe Pick for Dividend Investors at Motley Fool |
| 11-May-13 03:42PM | 6 Big Pharma Stocks With Lower Credit Risk Than U.S. Treasuries: Part II at Motley Fool |
| 02:36PM | London-Based Hedgie Focusing On Big Pharma at Motley Fool |
| 11:11AM | The First Step in Treating Type 2 Diabetes at Motley Fool |
| 11:10AM | Should You Own Pfizer Stock? at Wall St. Cheat Sheet |
| 11:00AM | Some Fish Oil Doesn't Help Some Patients in Some Countries at Motley Fool |
| 10:35AM | The 4 Best Large-Cap Companies for Workplace Diversity at Motley Fool |
| 10-May-13 02:30PM | Big Oil's Fall Holds Back a Flat Dow's Friday at Motley Fool |
| 02:21PM | No Fat in This Drug Launch at Motley Fool |
| 11:42AM | Marketing Without Innovation: a Merck Story YCharts |
| 11:30AM | Simcere Beats 1Q Earnings & Revenue Estimate Zacks |
| 11:20AM | Analysis: Drugmakers face more scrutiny of discordant U.S. prices Reuters |
| 10:40AM | What's Missing in This Market TheStreet |
| 09:31AM | Merck Becomes #21 Most Shorted Dow Stock, Replacing Travelers at Forbes |
| 08:36AM | Adcock Takeover May Value Company at $1.5 Billion, JPMorgan Says at Bloomberg |
| 08:26AM | The FDA Approval Of Merck's Cholesterol Lowerer, Liptruzet, Doesn't Help Its Credibility at Forbes |
| 06:53AM | GlaxoSmithKline, Merck to discount cancer vaccine in poor nations, NY Times says theflyonthewall.com |
| 09-May-13 08:16PM | Is the Golden Age of Blockbusters Over? at Motley Fool |
| 08:00PM | Markets Couldn't Hold Early Gains: Dow Falls 22 Points at Motley Fool |
| 06:07PM | Pharmas Failure: Drug Spending Finally Declines YCharts |
| 05:53PM | Drugmakers, health groups bring poor girls vaccine AP |
| 04:29PM | 3 Drug Catalysts to Watch in 2013 at Motley Fool |
| 02:45PM | Lawsuit alleges Merck discriminates against women AP |
| 02:45PM | Gardasil Is Good at Forbes |
| 02:28PM | Drugmakers, health groups bring poor girls vaccine AP |
| 12:20PM | Merck sales representative claims sexual bias, seeks over $100 million Reuters |
| 12:18PM | Will $15 Billion Work for This Troubled Drug Maker? at Motley Fool |
| 12:08PM | Lawsuit alleges Merck discriminates against women AP |
| 11:48AM | Lawsuit alleges Merck discriminates against women AP |
| 11:48AM | Review Of Depomed First Quarter 2013 Results at Seeking Alpha |
| 11:46AM | Merck's Liptruzet: A Cause For Shame? at Seeking Alpha |
| 11:32AM | Merck sales representative claims sexual bias, seeks over $100 million Reuters |
| 11:25AM | Merck sales rep claims sexual bias, seeks over $100 mln at Reuters |
| 10:30AM | Merck sales rep alleges sexual bias, seeks over $100 mln at Reuters |
| 09:39AM | [video] Biotech's Next Big Thing: ASCO at TheStreet |
| 09:04AM | Drugmakers, health groups bring poor girls vaccine AP |
| 09:02AM | Drugmakers, health groups bring poor girls vaccine AP |
| 09:00AM | Sanford Heisler Files $100m+ Discrimination Suit Against Pharma Giant Merck & Co., Inc. PR Newswire |
| 08:27AM | Merck And Glaxo Drop HPV Vaccine Price To Reach Girls In The Developing World at Forbes |
| 08:27AM | Great News: HPV Vaccine Prices Drop To Reach Girls In The Developing World at Forbes |
| 08:20AM | 5 Stocks This Legendary Value Investor Is Backing at Seeking Alpha |
|
| Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. It offers human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of cardiovascular, diabetes and obesity, respiratory, women's health and endocrine, inflammatory and infectious diseases, oncology, ophthalmology, and others. The company also provides vaccines, including preventive pediatric, adolescent, and adult vaccines. In addition, it discovers, develops, manufactures, and markets animal health products comprising vaccines, antibiotics, and anti-inflammatory drugs for respiratory diseases, as well as products for the treatment of fertility disorders. Further, the company manufactures and sells over-the-counter products consisting of non-drowsy antihistamines; decongestant-free cold/flu medicine for people with high blood pressure; nasal decongestant spray; and products for occasional constipation and frequent heartburn. Additionally, it offers foot care products, including topical antifungal, and foot and sneaker odor/wetness products; and sun care products, such as sun care lotions, sprays, and dry oils. The company serves drug wholesalers and retailers, hospitals, government agencies, physicians, physician distributors, veterinarians, animal producers, food chain and mass merchandiser outlets, club stores, and specialty channels, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. It has a collaboration with Sanofi Pasteur S.A. and Abide Therapeutics, Inc.; and has a collaboration and license agreement with Luminex Corporation. The company was founded in 1891 and is headquartered in Whitehouse Station, New Jersey. |
